News Sentiment

OPRX sentiment intelligence

OPTIMIZERx Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Health Information Services Read-through group
Latest close 6.41 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+3.6% over one week, +22.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction 3.6% Price confirming higher
Trend fit Trend inactive 22.6% over four weeks
Fair value -37.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 21
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingKey 8
Stock Titan 7
Investing.com 5
Investing.com Australia 2
GlobeNewswire 2
The Manila Times 1
StocksToTrade 1

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 8
Analyst action 5
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 45
The Manila Times Direct company coverage

OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent

OptimizeRx has launched CopayCue™, a new solution designed to increase the transparency of brand savings offers for physicians within the e-prescribing workflow. This technology uses real-time HCP prescribing intent data to deliver copay card and affordability information, aiming

Tone
Positive 70/100
Event
Market update
Published
30 Jun 2026 19:42
Source
The Manila Times
Investing.com Direct company coverage

OptimizeRx stock rises after launching CopayCue product

OptimizeRx Corp (NASDAQ:OPRX) shares rose after the company announced the launch of CopayCue, a new product designed to deliver brand savings offers directly within healthcare professionals' prescribing workflows. This technology aims to address medication affordability issues, w

Tone
Positive 72/100
Event
Market update
Published
30 Jun 2026 13:09
Source
Investing.com
StocksToTrade Direct company coverage

OptimizeRx Corporation (OPRX) Stock Price | Live Quotes & Charts | NASDAQ

This article provides live stock quotes and charts for OptimizeRx Corporation (OPRX), detailing its current stock price, daily change, and percentage change. It notes the absence of recent analyst ratings and earnings information. The content also features promotional material fo

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 13:09
Source
StocksToTrade
Investing.com Australia Direct company coverage

OptimizeRx stock rises after launching CopayCue product By Investing.com

OptimizeRx Corp (NASDAQ:OPRX) shares rose after the company announced the launch of CopayCue, a new technology designed to deliver brand savings offers within the prescribing workflow. CopayCue aims to address medication affordability issues by providing copay cards and affordabi

Tone
Positive 73/100
Event
Market update
Published
30 Jun 2026 12:40
Source
Investing.com Australia
Investing.com Direct company coverage

OptimizeRx launches CopayCue for prescription savings

OptimizeRx Corp. has launched CopayCue, a new technology designed to deliver prescription savings offers directly to physicians during the prescribing process, aiming to improve medication affordability and patient access. The solution has shown a significant increase in prescrip

Tone
Positive 66/100
Event
Market update
Published
30 Jun 2026 12:09
Source
Investing.com
Stock Titan Direct company coverage

OptimizeRx ties copay offers to physician intent at prescribing moment

OptimizeRx (Nasdaq: OPRX) has launched CopayCue, a new solution that delivers brand savings offers directly within e-prescribing workflows by leveraging real-time healthcare professional (HCP) prescribing intent data. This aims to overcome medication affordability barriers, which

Tone
Positive 66/100
Event
Market update
Published
30 Jun 2026 11:40
Source
Stock Titan
Investing.com Australia Direct company coverage

Stifel reiterates Buy on OptimizeRX stock, cites AI tool launch By Investing.com

Stifel maintained a Buy rating and $14.00 price target on OptimizeRX (NASDAQ: OPRX) after the company launched an AI-powered tool called Natural Language Audience Builder. Despite recent stock decline, InvestingPro analysis suggests the company is undervalued and analysts expect

Tone
Positive 73/100
Event
Analyst action
Published
29 Jun 2026 12:14
Source
Investing.com Australia
Investing.com Direct company coverage

OptimizeRx stock rating maintained at Market Outperform by Citizens

Citizens has maintained a Market Outperform rating on OptimizeRx (NASDAQ: OPRX) with a $9.00 price target, indicating a 77% upside from its current trading price despite a recent 58% decline. The firm highlighted OptimizeRx's undervalued status according to InvestingPro analysis

Tone
Positive 70/100
Event
Analyst action
Published
29 Jun 2026 09:14
Source
Investing.com
marketscreener.com Direct company coverage

OptimizeRx Corporation(NasdaqCM: OPRX) dropped from Russell 2000 Dynamic Index

OptimizeRx Corporation (NasdaqCM: OPRX) has been removed from the Russell 2000 Dynamic Index, as reported on MarketScreener. This announcement follows several recent company updates, including a change in its Chief Commercial Officer role and integration of its EHR network into a

Tone
Negative 33/100
Event
Market update
Published
29 Jun 2026 01:09
Source
marketscreener.com
Investing.com Direct company coverage

Stifel reiterates Buy on OptimizeRX stock, cites AI tool launch

Stifel maintained a Buy rating and $14.00 price target for OptimizeRX (NASDAQ: OPRX) after the company launched a new AI-powered tool. The Natural Language Audience Builder is designed to help pharmaceutical and agency marketers build custom healthcare provider audiences. Despite

Tone
Positive 64/100
Event
Analyst action
Published
28 Jun 2026 07:41
Source
Investing.com
Moomoo Direct company coverage

OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms

OptimizeRx has launched a Natural Language Audience Builder aimed at enhancing audience precision for life sciences digital signal processors (DSPs) and agency media planning platforms. This new tool leverages AI and deep learning to identify and refine healthcare professional (H

Tone
Positive 71/100
Event
Market update
Published
26 Jun 2026 02:40
Source
Moomoo
Investing.com Nigeria Direct company coverage

Citizens reiterates Market Outperform on OptimizeRX stock at forum By Investing.com

Citizens has reiterated a "Market Outperform" rating and a $9.00 price target for OptimizeRx (NASDAQ: OPRX) stock, despite the stock trading near its 52-week low. InvestingPro analysis suggests the company is undervalued, with a P/E ratio of 13.44 and a 16% free cash flow yield.

Tone
Positive 63/100
Event
Analyst action
Published
26 Jun 2026 02:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

OptimizeRx puts HCP audience building inside ad-buying platforms

OptimizeRx (Nasdaq: OPRX) has launched its Natural Language Audience Builder (NLAB), an AI-powered tool that allows life sciences companies and agencies to build, refine, and activate custom healthcare provider (HCP) audiences using natural-language prompts. This patent-pending t

Tone
Positive 71/100
Event
Market update
Published
25 Jun 2026 11:12
Source
Stock Titan
Investing.com Direct company coverage

Citizens reiterates Market Outperform on OptimizeRX stock at forum

Citizens reiterated a Market Outperform rating and $9.00 price target on OptimizeRx (NASDAQ:OPRX) shares, despite the stock trading near its 52-week low after a 63% decline in six months. The firm is hosting its annual Healthcare Services Forum where OptimizeRX will present, alon

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 09:12
Source
Investing.com
TradingKey Direct company coverage

OptimizeRx Corp (OPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of OptimizeRx Corp (OPRX), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 6.55 and is trading between a resistance le

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 01:41
Source
TradingKey
TradingKey Direct company coverage

OptimizeRx Corp (OPRX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of OptimizeRx Corp (OPRX), highlighting its current valuation score of 8.20 within the Software & IT Services industry. It notes the company's current P/E ratio of 12.67, comparing it to recent highs and lows. The analysis also indicates

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 09:39
Source
TradingKey
TradingKey Direct company coverage

OptimizeRx Corp (OPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for OptimizeRx Corp (OPRX), detailing its stock performance, market capitalization, and P/E ratio. It notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the compa

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 10:39
Source
TradingKey
TradingKey Direct company coverage

OptimizeRx Corp (OPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of OptimizeRx Corp's (OPRX) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and shows no record of stock splits. The page also presents current stock performance data, includ

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 10:39
Source
TradingKey
TradingKey Direct company coverage

OptimizeRx Corp (OPRX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of OptimizeRx Corp (OPRX), listing its major individual and institutional holders, their proportion of shares, and recent changes in holdings. It also provides a breakdown of shareholder types by investment category and historical in

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 10:39
Source
TradingKey
TradingKey Direct company coverage

OptimizeRx Corp (OPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for OptimizeRx Corp (OPRX), highlighting its current risk score of 4.19 within the Software & IT Services industry. The company's beta of 1.14 suggests it is more volatile than the S&P 500. The assessment includes detailed metrics on volati

Tone
Negative 36/100
Event
Market update
Published
17 Jun 2026 21:10
Source
TradingKey
TradingKey Direct company coverage

OptimizeRx Corp (OPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

OptimizeRx Corp (OPRX) currently holds an earnings forecast score of 8.67, ranking it 26th in the Software & IT Services industry. Analysts project an average price target of $24.00, with a consensus "Buy" rating based on 6 analyst reports. The company's next expected revenue is

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 20:10
Source
TradingKey
TradingKey Direct company coverage

OptimizeRx Corp (OPRX) Institutional Confidence

OptimizeRx Corp (OPRX) has an institutional shareholding score of 7.00, placing it 140th out of 489 in the Software & IT Services industry. Institutional investors hold 82.46% of shares, an increase of 8.32% quarter-over-quarter. The largest institutional shareholder is Bill Nygr

Tone
Positive 74/100
Event
Market update
Published
16 Jun 2026 22:10
Source
TradingKey
Stock Titan Direct company coverage

OptimizeRx (OPRX) director awarded 17,258 restricted stock units in Form 4 filing

OptimizeRx Corp director Presti Mariyamma Varghese was granted 17,258 restricted stock units (RSUs) of common stock, increasing her direct holdings to 30,318 shares. This award was provided at no cash cost per unit and signifies a contingent right to receive shares. The RSUs will

Tone
Neutral 50/100
Event
Balance sheet
Published
15 Jun 2026 12:11
Source
Stock Titan
Stock Titan Direct company coverage

OptimizeRx (NASDAQ: OPRX) holders add 1M plan shares, reject evergreen

OptimizeRx shareholders approved an amendment to the 2021 Equity Incentive Plan, increasing the shares available for awards by 1,000,000 to a total of 5,450,000. While all director nominees were elected and executive compensation was approved on an advisory basis, a proposal to a

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

OPRX SEC Filings - Optimizerx Corp 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Optimizerx (OPRX) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. Recent filings detail equity awards for executives Edward Stelmakh, Theresa Greco, and Doug Besch, an amended employment letter for Brendan

Tone
Positive 61/100
Event
Market update
Published
12 Jun 2026 08:10
Source
Stock Titan